Joel Isaacson & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Joel Isaacson & Co’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Hold	3,067	–	–	0.06%	146
2026 Q1	$2.37M	Sell	3,067 -6	-0.2%	-$4.59K	0.08%	117
2025 Q4	$2.37M	Hold	3,073	–	–	0.08%	117
2025 Q3	$1.73M	Hold	3,073	–	–	0.06%	132
2025 Q2	$1.61M	Sell	3,073 -225	-7%	-$126K	0.07%	121
2025 Q1	$2.09M	Hold	3,298	–	–	0.09%	99
2024 Q4	$2.35M	Sell	3,298 -25	-0.8%	-$21K	0.11%	89
2024 Q3	$3.49M	Hold	3,323	–	–	0.17%	61
2024 Q2	$3.49M	Buy	3,323 +24	+0.7%	+$23.3K	0.18%	54
2024 Q1	$3.18M	Buy	3,299 +2	+0.1%	+$1.9K	0.17%	56
2023 Q4	$2.9M	Buy	3,297 +31	+0.9%	+$25.5K	0.18%	55
2023 Q3	$2.69M	Buy	3,266 +38	+1%	+$29.9K	0.18%	54
2023 Q2	$2.32M	Hold	3,228	–	–	0.16%	65
2023 Q1	$2.65M	Sell	3,228 -25	-0.8%	-$18.9K	0.19%	57
2022 Q4	$2.35M	Buy	3,253 +14	+0.4%	+$10.3K	0.18%	62
2022 Q3	$2.23M	Sell	3,239 -2	-0.1%	-$1.26K	0.19%	57
2022 Q2	$1.92M	Sell	3,241 -5	-0.2%	-$3.25K	0.16%	64
2022 Q1	$2.35M	Sell	3,246 -6	-0.2%	-$3.8K	0.17%	61
2021 Q4	$2.05M	Buy	3,252 +6	+0.2%	+$3.69K	0.14%	73
2021 Q3	$1.96M	Hold	3,246	–	–	0.15%	67
2021 Q2	$1.81M	Sell	3,246 -1	-0%	-$507	0.14%	70
2021 Q1	$1.54M	Hold	3,247	–	–	0.13%	73
2020 Q4	$1.57M	Hold	3,247	–	–	0.15%	63
2020 Q3	$1.82M	Buy	3,247 +9	+0.3%	+$5.46K	0.24%	44
2020 Q2	$2.02M	Buy	3,238 +226	+8%	+$128K	0.29%	37
2020 Q1	$1.47M	Buy	3,012 +12	+0.4%	+$4.95K	0.26%	45
2019 Q4	$1.13M	Hold	3,000	–	–	0.15%	65
2019 Q3	$832K	Sell	3,000 -28	-0.9%	-$8.29K	0.12%	83
2019 Q2	$948K	Sell	3,028 -14	-0.5%	-$4.66K	0.14%	74
2019 Q1	$1.25M	Buy	3,042 +25	+0.8%	+$10.3K	0.18%	68
2018 Q4	$1.23M	Buy	3,017 +17	+0.6%	+$6.22K	0.2%	61
2018 Q3	$1.21M	Hold	3,000	–	–	0.19%	54
2018 Q2	$1.03M	Sell	3,000 -12	-0.4%	-$3.75K	0.17%	60
2018 Q1	$1.04M	Buy	3,012 +12	+0.4%	+$4.17K	0.18%	58
2017 Q4	$1.13M	Hold	3,000	–	–	0.2%	55
2017 Q3	$1.34M	Hold	3,000	–	–	0.25%	48
2017 Q2	$1.47M	Hold	3,000	–	–	0.28%	42
2017 Q1	$1.16M	Hold	3,000	–	–	0.23%	51
2016 Q4	$1.1M	Hold	3,000	–	–	0.22%	50
2016 Q3	$1.21M	Hold	3,000	–	–	0.25%	39
2016 Q2	$1.05M	Hold	3,000	–	–	0.22%	46
2016 Q1	$1.08M	Hold	3,000	–	–	0.24%	47
2015 Q4	$1.63M	Hold	3,000	–	–	0.4%	35
2015 Q3	$1.4M	Hold	3,000	–	–	0.37%	34
2015 Q2	$1.53M	Hold	3,000	–	–	0.39%	32
2015 Q1	$1.35M	Hold	3,000	–	–	0.34%	39
2014 Q4	$1.23M	Hold	3,000	–	–	0.33%	36
2014 Q3	$1.08M	Hold	3,000	–	–	0.33%	41
2014 Q2	$847K	Hold	3,000	–	–	0.27%	48
2014 Q1	$901K	Hold	3,000	–	–	0.3%	45
2013 Q4	$826K	Hold	3,000	–	–	0.3%	43
2013 Q3	$939K	Hold	3,000	–	–	0.38%	36
2013 Q2	$675K	Buy	+3,000	New	+$699K	0.32%	42

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Joel Isaacson & Co's REGN Position: Q2 2026 in Review

Joel Isaacson & Co held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 3,067 shares worth $1.91M. The position accounts for 0.06% of the portfolio, ranked #146.

Joel Isaacson & Co first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.49M in Q3 2024. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Joel Isaacson & Co held 3,067 shares of Regeneron Pharmaceuticals worth $1.91M as of Q2 2026.
Joel Isaacson & Co left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.06% of Joel Isaacson & Co's portfolio in Q2 2026, its #146 holding.
Joel Isaacson & Co first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Joel Isaacson & Co's Regeneron Pharmaceuticals position peaked at $3.49M in Q3 2024.
729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Joel Isaacson & Co's 13F filing for Q2 2026, filed 4 Aug 2026.